More FDA factoids: Total internal cost of reviewing all NDAs and BLAs during FY2009 was $855M, of which 60% was covered by PDUFA fees. (Source: http://www.bloomberg.com/news/2011-07-07/drug-review-procedures-for-fda-slow-innovation-republicans-say.html )